Baseline characteristics of the patients*
| Variable | No of patients (n = 29) | |
|---|---|---|
| CDAI, Crohn’s disease activity index; 6-MP, 6-mercaptopurine. | ||
| Sex (M/F) | 13/16 (44.8% M) | |
| Mean age (y) | 34.0 (10.8) | |
| Smoking status (yes/total) | 9/29 (31%) | |
| Initial CDAI | 296.7 (46.9) | |
| Median duration of disease (y) | 4 (1.5–8) | |
| Site of disease | ||
| Small bowel only | 10/29 (34.5%) | |
| Colon only | 5/29 (17.2%) | |
| Small bowel and colon | 14/29 (48.3%) | |
| Ileal resection | 5/29 (17.2%) | |
| Medications at entry | ||
| No medications | 5/29 (17.2%) | |
| Mesalamine | 10/29 (34.5%) | |
| Corticosteroid | 3/29 (10.3%) | |
| Azathioprine | 3/29 (10.3%) | |
| Mesalamine+corticosteroid | 1/29 (3.4%) | |
| Mesalamine+azathioprine/6-MP | 1/29 (3.4%) | |
| Corticosteroid+azathioprine/6-MP | 3/29 (10.3%) | |
| Mesalamine+corticosteroid+azathioprine/6-MP | 3/29 (10.3%) | |